Sophocarpidine (CAS 519-02-8) Market Report

Global Sophocarpidine (CAS 519-02-8) Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 28, 2022
  • PAGES：150
  • REPORT CODE：GMM781758
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Sophocarpidine is a white acicular crystal or crystalline powder with bitter taste. It is the main raw material for the production of oxymatrine and widely used in the treatment of liver diseases.

    Sophocarpidine (CAS 519-02-8) market report explains the definition, types, applications, major countries, and major players of the Sophocarpidine (CAS 519-02-8) market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Select Botanical

    • TIANSHAN Pharmaceuticals

    • Jiangsu Tiansheng Pharmaceutical

    • Qinghai Lake Pharmaceuticals

    • Tiansheng Pharmaceutical

    • Fujie Pharmaceutical

    • Selco Wirkstoffe Vertriebs GmbH

    • Indena

    • QHL Pharma

    By Type:

    • High Purity

    • Low Purity

    By End-User:

    • Pharmaceuticals

    • Pesticides

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Sophocarpidine (CAS 519-02-8) Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Sophocarpidine (CAS 519-02-8) Outlook to 2028- Original Forecasts

    • 2.2 Sophocarpidine (CAS 519-02-8) Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Sophocarpidine (CAS 519-02-8) Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Sophocarpidine (CAS 519-02-8) Market- Recent Developments

    • 6.1 Sophocarpidine (CAS 519-02-8) Market News and Developments

    • 6.2 Sophocarpidine (CAS 519-02-8) Market Deals Landscape

    7 Sophocarpidine (CAS 519-02-8) Raw Materials and Cost Structure Analysis

    • 7.1 Sophocarpidine (CAS 519-02-8) Key Raw Materials

    • 7.2 Sophocarpidine (CAS 519-02-8) Price Trend of Key Raw Materials

    • 7.3 Sophocarpidine (CAS 519-02-8) Key Suppliers of Raw Materials

    • 7.4 Sophocarpidine (CAS 519-02-8) Market Concentration Rate of Raw Materials

    • 7.5 Sophocarpidine (CAS 519-02-8) Cost Structure Analysis

      • 7.5.1 Sophocarpidine (CAS 519-02-8) Raw Materials Analysis

      • 7.5.2 Sophocarpidine (CAS 519-02-8) Labor Cost Analysis

      • 7.5.3 Sophocarpidine (CAS 519-02-8) Manufacturing Expenses Analysis

    8 Global Sophocarpidine (CAS 519-02-8) Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Sophocarpidine (CAS 519-02-8) Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Sophocarpidine (CAS 519-02-8) Export by Region (Top 10 Countries) (2017-2028)

    9 Global Sophocarpidine (CAS 519-02-8) Market Outlook by Types and Applications to 2022

    • 9.1 Global Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global High Purity Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Low Purity Consumption and Growth Rate (2017-2022)

    • 9.2 Global Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Pharmaceuticals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Pesticides Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Sophocarpidine (CAS 519-02-8) Market Analysis and Outlook till 2022

    • 10.1 Global Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.2.2 Canada Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.2.3 Mexico Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.2 UK Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.3 Spain Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.4 Belgium Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.5 France Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.6 Italy Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.7 Denmark Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.8 Finland Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.9 Norway Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.10 Sweden Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.11 Poland Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.12 Russia Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.3.13 Turkey Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.2 Japan Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.3 India Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.4 South Korea Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.5 Pakistan Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.6 Bangladesh Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.7 Indonesia Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.8 Thailand Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.9 Singapore Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.10 Malaysia Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.11 Philippines Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.4.12 Vietnam Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.5.2 Colombia Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.5.3 Chile Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.5.4 Argentina Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.5.5 Venezuela Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.5.6 Peru Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.5.7 Puerto Rico Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.5.8 Ecuador Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.6.2 Kuwait Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.6.3 Oman Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.6.4 Qatar Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.7.2 South Africa Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.7.3 Egypt Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.7.4 Algeria Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

      • 10.8.2 New Zealand Sophocarpidine (CAS 519-02-8) Consumption (2017-2022)

    11 Global Sophocarpidine (CAS 519-02-8) Competitive Analysis

    • 11.1 Select Botanical

      • 11.1.1 Select Botanical Company Details

      • 11.1.2 Select Botanical Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Select Botanical Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

      • 11.1.4 Select Botanical Sophocarpidine (CAS 519-02-8) Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 TIANSHAN Pharmaceuticals

      • 11.2.1 TIANSHAN Pharmaceuticals Company Details

      • 11.2.2 TIANSHAN Pharmaceuticals Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 TIANSHAN Pharmaceuticals Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

      • 11.2.4 TIANSHAN Pharmaceuticals Sophocarpidine (CAS 519-02-8) Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Jiangsu Tiansheng Pharmaceutical

      • 11.3.1 Jiangsu Tiansheng Pharmaceutical Company Details

      • 11.3.2 Jiangsu Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Jiangsu Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

      • 11.3.4 Jiangsu Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Qinghai Lake Pharmaceuticals

      • 11.4.1 Qinghai Lake Pharmaceuticals Company Details

      • 11.4.2 Qinghai Lake Pharmaceuticals Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Qinghai Lake Pharmaceuticals Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

      • 11.4.4 Qinghai Lake Pharmaceuticals Sophocarpidine (CAS 519-02-8) Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Tiansheng Pharmaceutical

      • 11.5.1 Tiansheng Pharmaceutical Company Details

      • 11.5.2 Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

      • 11.5.4 Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Fujie Pharmaceutical

      • 11.6.1 Fujie Pharmaceutical Company Details

      • 11.6.2 Fujie Pharmaceutical Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Fujie Pharmaceutical Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

      • 11.6.4 Fujie Pharmaceutical Sophocarpidine (CAS 519-02-8) Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Selco Wirkstoffe Vertriebs GmbH

      • 11.7.1 Selco Wirkstoffe Vertriebs GmbH Company Details

      • 11.7.2 Selco Wirkstoffe Vertriebs GmbH Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Selco Wirkstoffe Vertriebs GmbH Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

      • 11.7.4 Selco Wirkstoffe Vertriebs GmbH Sophocarpidine (CAS 519-02-8) Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Indena

      • 11.8.1 Indena Company Details

      • 11.8.2 Indena Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Indena Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

      • 11.8.4 Indena Sophocarpidine (CAS 519-02-8) Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 QHL Pharma

      • 11.9.1 QHL Pharma Company Details

      • 11.9.2 QHL Pharma Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 QHL Pharma Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

      • 11.9.4 QHL Pharma Sophocarpidine (CAS 519-02-8) Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    12 Global Sophocarpidine (CAS 519-02-8) Market Outlook by Types and Applications to 2028

    • 12.1 Global Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global High Purity Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Low Purity Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Pharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Pesticides Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Sophocarpidine (CAS 519-02-8) Market Analysis and Outlook to 2028

    • 13.1 Global Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.2.2 Canada Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.2 UK Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.3 Spain Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.5 France Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.6 Italy Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.8 Finland Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.9 Norway Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.11 Poland Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.12 Russia Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.2 Japan Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.3 India Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.5.3 Chile Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.5.6 Peru Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.6.3 Oman Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Sophocarpidine (CAS 519-02-8) Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Sophocarpidine (CAS 519-02-8)

    • Figure of Sophocarpidine (CAS 519-02-8) Picture

    • Table Global Sophocarpidine (CAS 519-02-8) Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Sophocarpidine (CAS 519-02-8) Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global High Purity Consumption and Growth Rate (2017-2022)

    • Figure Global Low Purity Consumption and Growth Rate (2017-2022)

    • Figure Global Pharmaceuticals Consumption and Growth Rate (2017-2022)

    • Figure Global Pesticides Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Sophocarpidine (CAS 519-02-8) Consumption by Country (2017-2022)

    • Table North America Sophocarpidine (CAS 519-02-8) Consumption by Country (2017-2022)

    • Figure United States Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Canada Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Mexico Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Table Europe Sophocarpidine (CAS 519-02-8) Consumption by Country (2017-2022)

    • Figure Germany Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure UK Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Spain Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Belgium Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure France Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Italy Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Denmark Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Finland Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Norway Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Sweden Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Poland Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Russia Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Turkey Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Table APAC Sophocarpidine (CAS 519-02-8) Consumption by Country (2017-2022)

    • Figure China Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Japan Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure India Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Thailand Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Singapore Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Philippines Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Table South America Sophocarpidine (CAS 519-02-8) Consumption by Country (2017-2022)

    • Figure Brazil Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Colombia Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Chile Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Argentina Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Peru Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Table GCC Sophocarpidine (CAS 519-02-8) Consumption by Country (2017-2022)

    • Figure Bahrain Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Oman Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Qatar Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Table Africa Sophocarpidine (CAS 519-02-8) Consumption by Country (2017-2022)

    • Figure Nigeria Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure South Africa Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Egypt Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure Algeria Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Table Oceania Sophocarpidine (CAS 519-02-8) Consumption by Country (2017-2022)

    • Figure Australia Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Sophocarpidine (CAS 519-02-8) Consumption and Growth Rate (2017-2022)

    • Table Select Botanical Company Details

    • Table Select Botanical Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Select Botanical Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

    • Table Select Botanical Sophocarpidine (CAS 519-02-8) Product Portfolio

    • Table TIANSHAN Pharmaceuticals Company Details

    • Table TIANSHAN Pharmaceuticals Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

    • Table TIANSHAN Pharmaceuticals Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

    • Table TIANSHAN Pharmaceuticals Sophocarpidine (CAS 519-02-8) Product Portfolio

    • Table Jiangsu Tiansheng Pharmaceutical Company Details

    • Table Jiangsu Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Jiangsu Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

    • Table Jiangsu Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Product Portfolio

    • Table Qinghai Lake Pharmaceuticals Company Details

    • Table Qinghai Lake Pharmaceuticals Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Qinghai Lake Pharmaceuticals Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

    • Table Qinghai Lake Pharmaceuticals Sophocarpidine (CAS 519-02-8) Product Portfolio

    • Table Tiansheng Pharmaceutical Company Details

    • Table Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

    • Table Tiansheng Pharmaceutical Sophocarpidine (CAS 519-02-8) Product Portfolio

    • Table Fujie Pharmaceutical Company Details

    • Table Fujie Pharmaceutical Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Fujie Pharmaceutical Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

    • Table Fujie Pharmaceutical Sophocarpidine (CAS 519-02-8) Product Portfolio

    • Table Selco Wirkstoffe Vertriebs GmbH Company Details

    • Table Selco Wirkstoffe Vertriebs GmbH Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Selco Wirkstoffe Vertriebs GmbH Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

    • Table Selco Wirkstoffe Vertriebs GmbH Sophocarpidine (CAS 519-02-8) Product Portfolio

    • Table Indena Company Details

    • Table Indena Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Indena Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

    • Table Indena Sophocarpidine (CAS 519-02-8) Product Portfolio

    • Table QHL Pharma Company Details

    • Table QHL Pharma Sophocarpidine (CAS 519-02-8) Sales, Price, Value and Gross Profit (2017-2022)

    • Table QHL Pharma Sophocarpidine (CAS 519-02-8) Main Business and Markets Served

    • Table QHL Pharma Sophocarpidine (CAS 519-02-8) Product Portfolio

    • Figure Global High Purity Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Low Purity Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pesticides Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Sophocarpidine (CAS 519-02-8) Consumption Forecast by Country (2022-2028)

    • Table North America Sophocarpidine (CAS 519-02-8) Consumption Forecast by Country (2022-2028)

    • Figure United States Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Sophocarpidine (CAS 519-02-8) Consumption Forecast by Country (2022-2028)

    • Figure Germany Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Sophocarpidine (CAS 519-02-8) Consumption Forecast by Country (2022-2028)

    • Figure China Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Sophocarpidine (CAS 519-02-8) Consumption Forecast by Country (2022-2028)

    • Figure Brazil Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Sophocarpidine (CAS 519-02-8) Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Sophocarpidine (CAS 519-02-8) Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Sophocarpidine (CAS 519-02-8) Consumption Forecast by Country (2022-2028)

    • Figure Australia Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Sophocarpidine (CAS 519-02-8) Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US